Navigation Links
AnaLisa DiFeo, Ph.D., recognized with the Liz Tilberis Scholarship
Date:12/1/2010

AnaLisa DiFeo, PhD, Instructor in the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine, has been honored by the Ovarian Cancer Research Fund (OCRF) with the Liz Tilberis Grant. Named for fashion icon Liz Tilberis who died of ovarian cancer, the grant is awarded to young researchers in their first faculty appointment who are conducting laboratory research that will advance ovarian cancer detection and treatment. Dr. DiFeo will receive $450,000 over three years to study chemotherapeutic resistance in epithelial ovarian cancer (EOC), the most lethal gynecologic malignancy in the United States.

"I am honored to be recognized by the OCRF with this prestigious award," said Dr. DiFeo. "Ovarian is one of the deadliest cancers, and we have a long way to go in improving detection and treatment. With this grant I plan to continue to study the mechanisms behind chemotherapy resistance in these tumors and hopefully identify a new drug target that will help circumvent it."

Multi-drug resistance and tumor recurrence after chemotherapy are common in women with EOC. Researchers have been unable to predict patient response to therapy because they do not have a thorough understanding of the complex mechanism within the tumor that causes drug resistance. Dr. DiFeo's research under the grant will be dedicated to studying potential new drug targets for adjunctive therapies that sensitize the tumor to chemotherapy. One such target is microRNAs, a class of RNA that regulates the expression of multiple genes.

Dr. DiFeo will study microRNA profiles and evaluate whether there is a difference in these profiles in EOC tumors that are sensitive to chemotherapy and those that are not. The main focus of her project is to determine the biological and functional relevance of the microRNAs that found to be associated chemoresistance.

The research team hopes to validate the clinical relevance and determine the function of one family of microRNAmiR181using a clinical cohort of ovarian cancer specimens. Using an ovarian cancer mouse model, they will evaluate if targeting miR181 sensitizes tumors previously resistant to chemotherapy. If so, the research team will have identified a new drug target that could overcome chemoresistance in EOC.

"We believe that microRNAs may play a critical role in chemoresistance and that they may represent predictive marker for personalized therapy for each patient," said Dr. DiFeo. "MicroRNAs may be the key to overcoming chemoresistance due to their ability to regulate multiple gene expression, and understanding the function of these miRNAs may provide a significant step forward in reducing the burden of disease."

A graduate of Mount Sinai School of Medicine, Dr. DiFeo's laboratory interests are focused on uncovering novel ways to improve the detection and treatment of ovarian cancer with a specific interest in understanding the mechanisms of ovarian cancer chemoresistance. The overall goal of the laboratory is to identify novel biomarkers of ovarian cancer therapeutic response and generate novel targeted molecular therapies that can work alone or in conjunction with current treatment options to combat ovarian cancer. In addition to her 2010 Liz Tilberis Award from OCRF, she was the recipient of the American Association of Cancer Research AstraZeneca Scholar-in-Training Award in 2008, and has also recently received a research grant from the Department of Defense.

Liz Tilberis was a fashion icon and editor-in-chief of Harper's Bazaar. The grant was established in her name in 2000, the year after she died of ovarian cancer. A national organization with headquarters in New York, OCRF is the largest private non-profit organization in the United States dedicated exclusively to funding ovarian cancer research. To date, OCRF has awarded 164 grants for ovarian cancer research, an investment of nearly $40 million.

Ovarian cancer is the deadliest of all gynecologic cancers and is the fifth leading cause of cancer death in women. Worldwide, about 200,000 women are diagnosed with ovarian cancer and 125,000 women die from this disease. In the United States alone, there will be approximately 22,000 new cases of ovarian cancer in the United States each year, and about 15,500 women will die of the disease. Currently there is no effective means of early detection.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Donald A. Deieso, Ph.D., Chairman & CEO, PeriGen, Inc. Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist
2. Lafarge North America Recognized by IBI and NBCH for Health & Productivity Leadership
3. Reno Children With Disabilities Profit From a Little Known but Internationally Recognized Non-Profit Organization as it Quietly Crosses the $200,000.00 Mark in Service Investment Into the Reno Area
4. Maria D. Solomon is Recognized by Continental Who’s Who Among Health Care Professionals
5. Cymetrix Board Member Recognized for Enhancing the Growth and Operations of the Companies He Advises
6. Illinois State Senator Cullerton Recognized for Advocacy Work on Mental Health Issues
7. Gene discovered for newly recognized disease in Amish children
8. Phyllis E. Thomson is Recognized by Continental Whos Who Among Health Care Professionals
9. OASIS Recognized for Brain Fitness Programming
10. TalentWise Named to Workforce Management's "The Hot List" for Fourth Consecutive Year TalentWise GM Todd Owens Recognized as HRO Today "2010 Superstar"
11. Dr. Mark Russell Recognized By Strathmores Whos Who Worldwide Publication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root ... Orleans. This is a new, greatly improved version of the Doctor Referral teaming dataset ... by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released by ...
(Date:6/24/2017)... York (PRWEB) , ... June 24, 2017 , ... ... the Dental365 family. Located at 217 Portion Road in Lake Ronkonkoma, Dental365 offers ... evenings and weekends so that visits to the dentist fit into their patients’ ...
(Date:6/23/2017)... ... 23, 2017 , ... By scoring 100% for fiscal management and accountability, the ... online charity evaluator, Charity Navigator, validating ANRF's work as a top charity in America. ... Charity Navigator and earns ANRF a spot on their “ 10 Charities Worth Watching ...
(Date:6/23/2017)... ... 2017 , ... Military Connection friend and veteran advocate Micaela Bensko ... Atlantic lounge. , Bensko is no stranger to the plight of the disabled. ... life to supporting our wounded veterans. A world-class photographer, her riveting photos “The Wounds ...
(Date:6/23/2017)... ... 2017 , ... Georgia State University will host the First ... two-day conference is focused on advancing scientific knowledge about the aggressive triple negative ... racial breast cancer-related disparities. The conference theme is “Illuminating Actionable Biology.” , Conference ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... Endo International plc (NASDAQ: ENDP ) today ... R. Goodwin , U.S. District Court Judge for the ... entered a case management order in MDL 2325, American ... (the "MDL") that includes a provision requiring plaintiffs in ... specific causation within one hundred twenty (120) days of ...
(Date:6/3/2017)... , June 3, 2017  Eli Lilly and ... that results from the Phase 3 MONARCH 2 ... & 6 inhibitor, in combination with fulvestrant, significantly ... fulvestrant alone in women with hormone-receptor-positive (HR+), human ... cancer who have relapsed or progressed after endocrine ...
Breaking Medicine Technology: